^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Go to data
Title:

Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

Excerpt:
...- For Cohorts 2, 3, 4, 5, 6 documented HER2 amplification identified through next generation sequencing by MSK-IMPACT or at another Clinical Laboratory Improvement Amendments (CLIA) laboratory, or documented HER2 amplification by in-situ hybridization (ISH) with HER2/CEP17 ratio ≥2.0 at a CLIA laboratory....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.

Published date:
05/16/2018
Excerpt:
Ado-trastuzumab emtansine showed efficacy in patients with HER2 amplified lung, endometrial, salivary gland, biliary tract and ovarian cancers as identified by NGS.
DOI:
10.1200/JCO.2018.36.15_suppl.2502
Trial ID: